Mentari Therapeutics, Inc. Common Stock
MTRI
2 hedge funds and large institutions have $14.5K invested in Mentari Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 2 closing their positions.
2.56% less ownership
Funds ownership: 3.03% → 0.47% (-2.6%)
50% less funds holding
Funds holding: 4 → 2 (-2)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $93.1K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$84K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$6.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.83K |
| 4 |
Advisory Services Network
Atlanta,
Georgia
|
-$6 |
| 5 |
TCI Wealth Advisors
Tucson,
Arizona
|
-$6 |
MTRI Hedge Fund Activity: Q2 2023 in Review
2 of the 6,391 institutional investors tracked by Wall St. Rank reported a position in Mentari Therapeutics, Inc. Common Stock (MTRI) for Q2 2023, worth a combined $14.5K — down 87% from $109K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of MTRI and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Renaissance Technologies, exiting entirely with an estimated $84K sold.
- 2 institutional investors held Mentari Therapeutics, Inc. Common Stock (MTRI) as of Q2 2023, down from 4 in Q1 2023.
- Funds reported $14.5K of Mentari Therapeutics, Inc. Common Stock stock for Q2 2023, down 87% quarter-over-quarter.
- 0 funds opened new Mentari Therapeutics, Inc. Common Stock positions in Q2 2023 and 2 closed out, a net change of -2 holders.
- The largest Mentari Therapeutics, Inc. Common Stock seller in Q2 2023 was Renaissance Technologies, an estimated $84K sold.
Based on aggregated 13F filings for Q2 2023.